Mycobacterium Infections, Nontuberculous
Infections with nontuberculous mycobacteria (atypical mycobacteria): M. kansasii, M. marinum, M. scrofulaceum, M. flavescens, M. gordonae, M. obuense, M. gilvum, M. duvali, M. szulgai, M. intracellulare (see MYCOBACTERIUM AVIUM COMPLEX;), M. xenopi (littorale), M. ulcerans, M. buruli, M. terrae, M. fortuitum (minetti, giae), M. chelonae, M. leprae.
Subtype terms (4)
More specific conditions that are subtypes of Mycobacterium Infections, Nontuberculous in the MeSH hierarchy.
- Buruli Ulcer
7 drugs (5 approved, 2 experimental)
- Leprosy
20 drugs (12 approved, 8 experimental)
- Mycobacterium avium-intracellulare Infection
24 drugs (21 approved, 3 experimental)
- Paratuberculosis
Drugs by status
Approved for this indication (1)
Phase 4 trials (4)
Phase 3 trials (2)
Phase 1 trials (2)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (27)
- Duke University
- Emory University
- Georgetown University
- University of Washington
- Johns Hopkins University
- New York University
- Oregon Health and Science University
- Stanford University
- The Oregon Clinic
- University of Iowa
- University of Kansas
- University of Miami
- University of Toronto
- Yale University
- Mayo Clinic
- University of California, San Diego
- University of California, San Francisco
- University of Chicago
- University of Colorado, Denver
- Medical University of South Carolina
- Louisiana State University
- University of North Carolina at Chapel Hill
- University of Texas, Tyler
- University of Paris
- Insmed, Inc.
- EvergreenHealth
- University of Picardie Jules Verne
Organization Involved with Phase 2 Indications (10)
Organization Involved with Phase 1 Indications (1)